Evaluation of idursulfase for the treatment of mucopolysaccharidosis II (Hunter syndrome)

Expert Opinion on Orphan Drugs

Volumn 1, Issue 1, 2013, Pages 89-98

  Scarpa, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Drug evaluation; Enzyme replacement therapy; Hunter syndroM.E.; Idursulfase; Mucopolysaccharidosis II

Indexed keywords

DRUG ANTIBODY; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

ANXIETY DISORDER; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; GROWTH; HEALTH CARE ACCESS; HUMAN; HUNTER SYNDROME; INFUSION RELATED REACTION; LIMB PAIN; LIVER LEVEL; SPLEEN; THORAX PAIN; URINE LEVEL; VISUAL DISORDER; WALKING;

EID: 84896737145     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.738182     Document Type: Article

References (61)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. McGraw-Hill; New York: 2001. p. 3421-52
2. Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA 1973;70:2134-8
3. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6
4. Ben Turkia H, Tebib N, Azzouz H, et al. Incidence of mucopolysaccharidoses in Tunisia. Tunis Med 2009;87:782-5
5. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-7
6. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:e10
7. Poupetova H, Ledvinova J, Berna L, et al. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010;33:387-96
8. Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87-92
9. Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan. 1984-2004. Am J Med Genet A 2009;149A:960-4
10. Wraith JE, Beck M, Giugliani R, et al. Initial report from the Hunter Outcome Survey. Genet Med 2008;10:508-16
11. Schwartz IV, Ribeiro MG, Mota JG, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2007;96:63-70
12. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121:e377-86
13. Young ID, Harper PS, Archer IM, Newcombe RG. A clinical and genetic study of Hunter's syndrome. 1 Heterogeneity. J Med Genet 1982;19:401-7
14. Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983;25:481-9
15. Jones SA, Almassy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009;32:534-43
16. Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child 1982;57:828-36
17. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77
18. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics 2009;124:e1228-39
19. Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr 2011;171(1):181-8
20. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010;33:589-604
21. Scarpa M, Almassy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011;6:72
22. Coppa GV, Gabrielli O, Zampini L, et al. Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Pediatr Med Chir 1995;17:227-35
23. McKinnis EJ, Sulzbacher S, Rutledge JC, et al. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996;129:145-8
24. Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant 2000;25:1093-7
25. Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009;154:733-7
26. Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-29
27. Vellodi A, Young E, Cooper A, et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-48
28. Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010;47:59-69
29. Green Cross Corporation. Green Cross gains market approval with the world's 2nd orphan drug for Hunter syndrome in South Korea. 12 January 2012. Available from: http://eng.greencross. com/ [Accessed 6 July] 2012
30. Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159:1082-91
31. Delgadillo V, O'Callaghan M del M, Artuch R, et al. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011;34:1039-44
32. de Ruijter J, Valstar MJ, Narajczyk M, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012;71:110-20
33. Marucha J, Tylki-Szymanska A, Jakobkiewicz-Banecka J, et al. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am J Med Genet A 2011;155A:2257-62
34. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73
35. Elaprase- (idursulfase) solution for intravenous infusion [prescribing information]. Shire Human Genetic Therapies, Inc; Cambridge, MA: 2011
36. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007;90:329-37
37. Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011;13:95-101
38. Schulze-Frenking G, Jones SA, Roberts J, et al. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011;34:203-8
39. Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011;13:102-9
40. Vellodi A. Mucopolysaccharidosis type II: guidelines for assessment, monitoring and enzyme replacement therapy (ERT). Available from: http://www. specialisedservices.nhs.uk/library/23/ Guidelines-for-Mucopolysaccharidosis- Type-II.pdf [Accessed 2 July] 2012
41. McGill JJ, Goldblatt J, Peters H, et al. Guidelines for the treatment of mucopolysaccharidosis type II (MPS II) through the Life Saving Drugs Program. Available from: http://www.health.gov. au/internet/main/publishing.nsf/Content/ lsdp-info/#Idursulfase [Accessed 2 July] 2012
42. Ontario Public Drug Programs Exceptional Access Program: Elaprase (idursulfase) -Reimbursement Guidelines. Revision 3 (June 2011). Available from: http://www.health.gov. on.ca/english/providers/program/drugs/ pdf/elaprase-reimburse.pdf [Accessed July 19] 2012
43. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005;98:829-36
44. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56:2407-19
45. OnePath- Services. Available from: http://www.elaprase.com/healthcare/ about-elaprase/onepath/ [Accessed 2 July 2012]
46. Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 2012;101:e42-7
47. Giugliani R, Hwu PWL, Tylki-Szymanska A, Whiteman DAH. A multi-center, open-label study evaluating safety and clinical outcomes in young children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. 12th International symposium on MPS and related diseases: 28 June - 1 July, 2012. Noordwijkerhout, the Netherlands; Abstract P100
48. Lampe C, Bosserhoff A, Burton BK, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe (neuronopathic) phenotype: an international case series. Final programme and abstracts from the 12th International symposium on MPS and related diseases; 28 June - 1 July, Noordwijkerhout, the Netherlands; Abstract S08.6
49. Tuschl K, Gal A, Paschke E, et al. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005;32:270-2
50. Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis 2010;5:14
51. Manara R, Rampazzo A, Cananzi M, et al. Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution. J Inherit Metab Dis 2010;DOI: 10.1007/s10545-009-9023-8
52. Jurecka A, Krumina Z, Zuber Z, et al. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. Am J Med Genet A 2012;158A:450-4
53. Jurecka A, Zuber A, Opoka-Winiarska V, et al. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 2012;DOI: 10.1016/j.ymgme.2012.08.013
54. Felice BR, Wright TL, Boyd RB, et al. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 2011;39:879-92
55. Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 2012;7:e30341
56. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22
57. Clarke LA. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med 2008;10:e1
58. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-7
59. Kobialka S, Beuret N, Ben-Tekaya H, Spiess M. Glycosaminoglycan chains affect exocytic and endocytic protein traffic. Traffic 2009;10:1845-55
60. Settembre C, Arteaga-Solis E, Ballabio A, Karsenty G. Self-eating in skeletal development: implications for lysosomal storage disorders. Autophagy 2009;5:228-9
61. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000;1-27